{"Clinical Trial ID": "NCT00322374", "Intervention": ["INTERVENTION 1:", "Ixabepilone 25 mg^m2 + Epirubin 75 mg^m2", "Participants received 25 mg/m^2 of Ixabepilone as a 3-hour IV infusion after a 3- to 5-minute IV infusion of 75 mg/m^2 of epirubicin every 21 days.", "INTERVENTION 2:", "Ixabepilone 30 mg^m2 + Epirubin 75 mg^m2", "Participants received 30 mg/m^2 of Ixabepilone as a 3-hour IV infusion after a 3- to 5-minute IV infusion of 75 mg/m^2 of epirubicin every 21 days."], "Eligibility": ["Incorporation criteria:", "Females 18 years of age", "A diagnosis of metastatic breast cancer confirmed histologically or cytologically", "A measurable or non-measurable disease defined by the criteria for assessing response in solid tumours (RECIST)", "- Exclusion criteria:", "Number of previous chemotherapy treatment lines in the metastatic setting 2"], "Results": ["Performance measures:", "Number of participants with a Toxic Limit Dose (DLT)", "One of the following substances is considered to be related to ixabepilone, epirubicin or combination occurring in cycle 1: the absolute number of neutrophils <500 cells/mm^3 for 7 consecutive days or febrile neutropenia of any duration;Grade(Gr)4 thrombocytopenia <25,000 cells/mm^3 or Gr3 with bleeding requiring platelet transfusion;Any other non-haematological drug-related toxicity, with the exception of the GR3 injection site reaction, fatigue, transient arthralgia/myalgia;", "Time limit: From base to end of cycle 1 (Day 21)", "Results 1:", "Ixabepilone 25 mg^m2 + Epirubin 75 mg^m2", "Description of the arm/group: Participants received 25 mg/m^2 of Ixabepilone as a 3-hour IV infusion after an IV infusion of 3-5 minutes 75 mg/m^2 of epirubicin every 21 days.", "Total number of participants analysed: 6", "Type of measurement: Number", "Unit of measure: Participants with DLT: Grade 4 neutropenia (severe): 1", "Total participants with a DLT: 1", "Participants without DLT: 5", "Results 2:", "Ixabepilone 30 mg^m2 + Epirubin 75 mg^m2", "Description of the arm/group: Participants received 30 mg/m^2 of Ixabepilone as a 3-hour IV infusion after an IV infusion of 3-5 minutes 75 mg/m^2 of epirubicin every 21 days.", "Total number of participants analysed: 6", "Type of measurement: Number", "Unit of measure: Participants with DLT: Grade 4 neutropenia (severe): 1", "Total participants with a DLT: 1", "Participants without DLT: 5"], "Adverse Events": ["Undesirable Events 1:", "Total: 2/6 (33.33 per cent)", "ANEMIA 0/6 (0.00 %)", "NEUTROPENIA 0/6 (0.00 %)", "NEUTROPENIA FEBRILE 0/6 (0.00 %)", "FEBRUILE BONE MAROW APLASIA 0/6 (0.00 %)", "NAUSEA 0/6 (0.00 %)", "VOIX 1/6 (16.67%)", "PYREXIA 0/6 (0.00 %)", "HYPERSENSITIVITY 1/6 (16.67%)", "- PLATELET CUNT DECREASED 0/6 (0.00 %)", "- BACK SIZE 0/6 (0.00 %)", "SYNCOPE 0/6 (0.00 %)", "- CEREBROVASCULAR ACCIDENT 0/6 (0.00 %)", "Adverse Events 2:", "Total: 8/30 (26.67%)", "ANAEMIA 1/30 (3.33%)", "NEUTROPENIA 0/30 (0.00 %)", "NEUTROPENIA FEBRILE 1/30 (3.33%)", "FEBRUILE BONE MAROW APLASIA 2/30 (6.67%)", "NAUSEA 2/30 (6.67%)", "VOIX 0/30 (0.00 %)", "PYREXIA 2/30 (6.67%)", "HYPERSENSITIVITY 0/30 (0.00 %)", "DECLARED PLATE CUNT 0/30 (0.00 %)", "- BACK SIZE 1/30 (3.33%)", "SYNCOPE 0/30 (0.00 %)", "- CEREBROVASCULAR ACCIDENT 1/30 (3.33%)"]}